A health system can boast excellent clean-claim rates and low AR days—and still leave millions on the table.
Why?
Because lagging metrics can create the wrong incentives.
When revenue cycle teams are heavily measured on accelerating AR and closing accounts, the path of least resistance is often to accept the payer’s downgrade. It’s faster to write off a complex clinical validation denial or accept observation status than to build and pursue a sophisticated clinical appeal.
The goal shouldn’t be to minimize the friction of closing an account.
It should be to maximize net collectible revenue from defensible claims.
Pursuing high-value, defensible denials isn’t inefficiency. It’s revenue protection.
Sometimes the financially responsible decision is to let an account age in AR while you fight a downgraded DRG or an inpatient medical necessity denial—when the expected recovery justifies it.
CFOs shouldn’t just ask whether AR is moving.
They should ask:
Are we optimizing for speed—or for full contractual yield?